Microcap Ledger Vivani Medical, Inc. $VANI
Facts as of . Built from SEC filings and our own data. Small caps move fast; check the latest filings.
Snapshot
- Exchange
- Nasdaq Capital Market
- Sector
- Electromedical & Electrotherapeutic Apparatus
- Headquarters
- Alameda, CA
- Fiscal year end
- December 31
- Shares outstanding
- 90,203,356 [10-Q 2026-08-13]
What the company doesAI summary of filing
Vivani Medical, Inc. is a clinical-stage biopharmaceutical company developing miniature, ultra long-acting subdermal drug implants using its proprietary NanoPortal technology to deliver medicines for chronic diseases. The company's lead programs include NPM-139 (semaglutide implant for chronic weight management, expected to enter clinical trials in mid-2026), NPM-133 (semaglutide implant for type 2 diabetes), NPM-115 (exenatide implant for chronic weight management, currently in clinical development), and OKV-119 (exenatide implant for obesity and diabetes in companion animals, developed with partner Okava Pharmaceuticals). Vivani has not yet generated revenue from product sales and is dependent on securing regulatory approval and completing clinical development of its product candidates. [10-K 2026-03-26]
Financial health
| Period | Revenue | Net income | Operating cash flow | Cash | Filing |
|---|---|---|---|---|---|
| 6 months to Jun 2026 | — | −$13.15M | −$12.23M | $19.89M | [10-Q 2026-08-13] |
| FY ended Dec 2025 | $0.00 | $26.61M | −$24.32M | $16.23M | [10-K 2026-03-26] |
| FY ended Dec 2024 | $0.00 | $23.49M | −$20.79M | $18.35M | [10-K 2025-03-31] |
- Quarterly cash burn
- −$6.12M
- Cash runway Estimate
- ~9.8 months
Capital structure and dilution
| Date | Shares outstanding | Filing |
|---|---|---|
| 2024-11-12 | 59,234,689 | [10-Q 2024-11-13] |
| 2025-03-28 | 59,242,903 | [10-K 2025-03-31] |
| 2025-05-12 | 59,243,903 | [10-Q 2025-05-13] |
| 2025-08-12 | 59,243,903 | [10-Q 2025-08-13] |
| 2025-11-12 | 72,952,235 | [10-Q 2025-11-13] |
| 2026-03-25 | 84,647,803 | [10-K 2026-03-26] |
| 2026-05-12 | 86,235,104 | [10-Q 2026-05-13] |
| 2026-08-13 | 90,203,356 | [10-Q 2026-08-13] |
- Shelf registration
- S-3 filed 2024-04-22; declared effective 2024-05-03 [S-3 2024-04-22]
Listing status
Current status: No Form 8-K Item 3.01 (listing notice) filings in the last 24 months, as of 2026-10-11.
Who owns it
| Date | Insider | Type | Shares | Price | Filing |
|---|---|---|---|---|---|
| 2026-07-15 | Williams Gregg | buy | 793,650 | $1.26 | [4 2026-07-16] |
Catalysts and calendar
| Date | Type | Title |
|---|---|---|
| 2026-09-25 | 424B5 | Prospectus or prospectus supplement |
| 2026-09-16 | 8-K | Regulation FD disclosure |
| 2026-08-17 | 8-K | Regulation FD disclosure |
| 2026-08-13 | 8-K | Results of operations; Regulation FD disclosure |
| 2026-08-13 | 10-Q | Quarterly report |
| 2026-08-06 | 8-K | Regulation FD disclosure |
| 2026-07-16 | 8-K | Regulation FD disclosure |
| 2026-07-07 | 8-K | Material agreement entered; Other events |
| 2026-06-30 | 8-K | Director or officer change; Shareholder vote results; Other events |
| 2026-06-04 | 8-K | Regulation FD disclosure |
| 2026-05-19 | 13D/A | Beneficial ownership report (5%+ holder) |
| 2026-05-13 | 8-K | Results of operations; Regulation FD disclosure |
Alerts for $VANI
Email me when Vivani Medical, Inc. files an offering, gets a deficiency notice, or moves sharply.
Facts as of . Small caps move fast; check the latest filings.